SRPT vs. CLS

In the year-to-date period, SRPT achieves a -50.29% return, which is significantly lower than CLS's -3.52% return. Over the past 10 years, SRPT has underperformed CLS with an annualized return of 16.68%, while CLS has yielded a comparatively higher 22.08% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SRPT Sharpe Ratio is -0.79, which is lower than the CLS Sharpe Ratio of 1.38. The chart below compares the historical Sharpe Ratios of SRPT and CLS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SRPT nor CLS has paid dividends to shareholders.

The maximum SRPT drawdown since its inception was -98.17%, roughly equal to the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for SRPT and CLS. For additional features, visit the drawdowns tool.

The current volatility for Sarepta Therapeutics, Inc. (SRPT) is 25.47%, while Celestica Inc. (CLS) has a volatility of 31.13%. This indicates that SRPT experiences smaller price fluctuations and is considered to be less risky than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.